Related Experiment Video
Updated: May 3, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Neuroprotective effects of erythropoiesis-stimulating agents in term and preterm neonates
Amber M Messier1, Robin K Ohls
1Division of Neonatology, Department of Pediatrics, University of New Mexico, Albuquerque, New Mexico, USA.
Purpose Of Review:
The use of erythropoiesis-stimulating agents (ESAs) such as erythropoietin and darbepoetin in preterm and term infants has been studied for over 20 years. Recent investigations have explored the potential neuroprotective effects of ESAs. We review the recent clinical trials and experimental animal models that provide evidence in support of using ESA to improve the neurodevelopmental outcomes in term and preterm infants.
Recent Findings:
Continued work using animal models have confirmed the neuroprotective properties of ESAs, including promotion of oligodendrocyte development in the face of neuronal injury. Clinical studies in term and preterm infants have reported the neuroprotective effects following ESA administration, and improved neurodevelopmental outcomes have been reported in the studies of preterm infants.
Summary:
ESAs show great promise in preventing and treating brain injury in term and preterm infants.
More Related Videos
Related Concept Videos
Factors Affecting Erythropoiesis
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Erythropoiesis
Teratogenicity
Pharmacokinetics in Pediatric Patients: Drug Distribution

